Cargando…

Stakeholder Perspectives of Australia’s National HPV Vaccination Program

Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standa...

Descripción completa

Detalles Bibliográficos
Autores principales: Swift, Caitlin, Dey, Aditi, Rashid, Harunor, Clark, Katrina, Manocha, Ramesh, Brotherton, Julia, Beard, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692920/
https://www.ncbi.nlm.nih.gov/pubmed/36423072
http://dx.doi.org/10.3390/vaccines10111976
_version_ 1784837396877017088
author Swift, Caitlin
Dey, Aditi
Rashid, Harunor
Clark, Katrina
Manocha, Ramesh
Brotherton, Julia
Beard, Frank
author_facet Swift, Caitlin
Dey, Aditi
Rashid, Harunor
Clark, Katrina
Manocha, Ramesh
Brotherton, Julia
Beard, Frank
author_sort Swift, Caitlin
collection PubMed
description Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements. However, course completion rates have not increased as much as anticipated due to the 6–12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia’s HPV vaccination program is perceived as highly successful, measures to further enhance the program’s impact and mitigate potential threats are important.
format Online
Article
Text
id pubmed-9692920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96929202022-11-26 Stakeholder Perspectives of Australia’s National HPV Vaccination Program Swift, Caitlin Dey, Aditi Rashid, Harunor Clark, Katrina Manocha, Ramesh Brotherton, Julia Beard, Frank Vaccines (Basel) Article Australia has been a world leader in human papillomavirus (HPV) vaccination and was the first country to implement a fully funded national HPV vaccination program, from 2007 for girls and 2013 for boys. In 2018 the program changed from a 4-valent to 9-valent HPV vaccine and a 3-dose to 2-dose standard schedule. We assessed stakeholder perspectives on factors influencing program outcomes and impact as part of a comprehensive program evaluation. In late 2019 and early 2020, we conducted 26 interviews with 42 key stakeholder participants and received 1513 survey responses from stakeholders including general practice staff and school-based nurse immunisers. Findings included that the 2-dose schedule is better accepted by schools and students and has reduced program cost and resource requirements. However, course completion rates have not increased as much as anticipated due to the 6–12 month dosing interval and reduced opportunities for school-based catch-up vaccination. Major reported barriers to increased vaccine coverage were absenteeism and consent form return. Vaccine hesitancy is not currently a major issue but remains a potential threat to the program. While Australia’s HPV vaccination program is perceived as highly successful, measures to further enhance the program’s impact and mitigate potential threats are important. MDPI 2022-11-21 /pmc/articles/PMC9692920/ /pubmed/36423072 http://dx.doi.org/10.3390/vaccines10111976 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Swift, Caitlin
Dey, Aditi
Rashid, Harunor
Clark, Katrina
Manocha, Ramesh
Brotherton, Julia
Beard, Frank
Stakeholder Perspectives of Australia’s National HPV Vaccination Program
title Stakeholder Perspectives of Australia’s National HPV Vaccination Program
title_full Stakeholder Perspectives of Australia’s National HPV Vaccination Program
title_fullStr Stakeholder Perspectives of Australia’s National HPV Vaccination Program
title_full_unstemmed Stakeholder Perspectives of Australia’s National HPV Vaccination Program
title_short Stakeholder Perspectives of Australia’s National HPV Vaccination Program
title_sort stakeholder perspectives of australia’s national hpv vaccination program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692920/
https://www.ncbi.nlm.nih.gov/pubmed/36423072
http://dx.doi.org/10.3390/vaccines10111976
work_keys_str_mv AT swiftcaitlin stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram
AT deyaditi stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram
AT rashidharunor stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram
AT clarkkatrina stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram
AT manocharamesh stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram
AT brothertonjulia stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram
AT beardfrank stakeholderperspectivesofaustraliasnationalhpvvaccinationprogram